These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10155313)

  • 41. [Influence of the granulocyte growth factor on the cost of bone marrow autografts in oncologic hematology].
    Brice P; Godin S; Libert O; Marolleau JP; Makki J; Extra JM; Faure P; Gisselbrecht C
    Presse Med; 1994 Oct; 23(33):1512-5. PubMed ID: 7529921
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lenograstim administration to HLA-identical donor-recipient pairs to accelerate marrow recovery post-transplant.
    Atkinson K; Fay K; Nivison-Smith I; Downs K
    Bone Marrow Transplant; 1997 Jan; 19(1):15-21. PubMed ID: 9012926
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of autologous bone marrow transplantation.
    Lawless GD
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S11-4. PubMed ID: 8846240
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim).
    Ono M
    Eur J Cancer; 1994; 30A Suppl 3():S7-11. PubMed ID: 7535073
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness.
    Faucher C; le Corroller AG; Blaise D; Novakovitch G; Manonni P; Moatti JP; Maraninchi D
    Bone Marrow Transplant; 1994 Dec; 14(6):895-901. PubMed ID: 7536070
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
    Chevallier B; Chollet P; Merrouche Y; Roche H; Fumoleau P; Kerbrat P; Genot JY; Fargeot P; Olivier JP; Fizames C
    J Clin Oncol; 1995 Jul; 13(7):1564-71. PubMed ID: 7541448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma.
    Dranitsaris G; Altmayer C; Quirt I
    Pharmacoeconomics; 1997 Jun; 11(6):566-77. PubMed ID: 10173030
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.
    Orciuolo E; Buda G; Marturano E; Mauro E; Milone G; Cangialosi C; Di Renzo N; Pastore D; Specchia G; De Paolis MR; Mazza P; Pietrantuono G; Petrini M
    Leuk Res; 2011 Jul; 35(7):899-903. PubMed ID: 21134693
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
    Kim IH; Park SK; Suh OK; Oh JM
    Curr Med Res Opin; 2003; 19(8):753-9. PubMed ID: 14687447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the bench.
    Hui CH; Hughes TP
    Leuk Lymphoma; 2006 Sep; 47(9):1721-3. PubMed ID: 17064975
    [No Abstract]   [Full Text] [Related]  

  • 52. The clinical benefits of recombinant human granulocyte colony stimulating factor in the treatment of cancer patients.
    Bacigalupo A
    Eur J Cancer; 1994; 30A Suppl 3():S26-9. PubMed ID: 7535069
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma.
    Badalamenti G; Incorvaia L; Provenzano S; Bronte G; Leto G; Fulfaro F; Maltese G
    Anticancer Res; 2013 Feb; 33(2):679-84. PubMed ID: 23393367
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An economic evaluation of the use of granulocyte colony-stimulating factor after bone marrow transplantation in children.
    Duncan N; Hewetson M; Atra A; Dick G; Pinkerton R
    Pharmacoeconomics; 1997 Feb; 11(2):169-74. PubMed ID: 10165826
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection.
    de Lalla F; Pellizzer G; Strazzabosco M; Martini Z; Du Jardin G; Lora L; Fabris P; Benedetti P; Erle G
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1094-8. PubMed ID: 11257020
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
    Demirer T; Buckner CD; Appelbaum FR; Petersen FB; Rowley S; Weaver CH; Lilleby K; Sanders J; Chauncey T; Storb R
    Bone Marrow Transplant; 1995 Jun; 15(6):915-22. PubMed ID: 7581091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Can sequential administration minimise the cost of high dose chemotherapy? An economic assessment in inflammatory breast cancer.
    Marino P; Le Corroller AG; Palangié T; Janvier M; Fabbro M; Molinier L; Delozier T; Livartowski A; Moatti JP; Viens P;
    Pharmacoeconomics; 2003; 21(11):807-18. PubMed ID: 12859221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Costs of peripheral blood progenitor cell transplantation using whole blood mobilised by filgrastim as compared with autologous bone marrow transplantation in non-Hodgkin's lymphoma.
    Uyl-de Groot CA; Ossenkoppele GJ; Buijt I; Huijgens PC
    Pharmacoeconomics; 1999 Mar; 15(3):305-11. PubMed ID: 10537437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial.
    Luce BR; Singer JW; Weschler JM; Buckner CD; Sheingold SH; Shannon-Dorcy K; Appelbaum FR; Nemunaitis J
    Pharmacoeconomics; 1994 Jul; 6(1):42-8. PubMed ID: 10172083
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.